In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Preparing For Off-Label Drug Use In The Real World (Part 1 Of 2)

This article was originally published in The Pink Sheet Daily

Executive Summary

Plans are acquiring the tools to monitor and assess the risk/benefit of drug use outside of the approved indication. Smart companies are working with payers to understand their concerns around off-label use and the data requirements in support of it.

You may also be interested in...



Clinical, Not Real-World, Data is Still The Key To On- And Off-Label Reimbursement (Part 2)

While payers have ever-more sophisticated datasets for observing drug use in the clinic, such information generally is “inconclusive” for reimbursement decisions, a managed care executive cautions.

Lilly’s Zyprexa Off-Label Settlement: Record Fine, Routine Compliance Deal

Lilly agreed to pay $1.4 billion in criminal and civil fines and pled guilty to misbranding its antipsychotic drug Zyprexa in a settlement with the U.S. Department of Justice. Despite the record-breaking sum, however, the terms in the accompanying corporate integrity agreement are similar to previous CIAs

Mesoblast’s Late-Stage Pipeline Could Be Game Changing: Are Investors Paying Attention?

Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.

Topics

Related Companies

UsernamePublicRestriction

Register

PS073227

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel